- Home
- UPST vs LNTH Comparison
UPST vs LNTH Comparison
Compare UPST & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UPST | LNTH |
|---|---|---|
| Founded | 2012 | 1956 |
| Country | United States | United States |
| Employees | N/A | 808 |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.2B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | UPST | LNTH |
|---|---|---|
| Price | $46.62 | $63.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 6 |
| Target Price | $60.79 | ★ $74.17 |
| AVG Volume (30 Days) | ★ 5.4M | 1.1M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.26 | ★ 2.39 |
| Revenue | $997,748,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | $56.14 | $0.01 |
| Revenue Next Year | $22.99 | $1.24 |
| P/E Ratio | $182.25 | ★ $26.45 |
| Revenue Growth | ★ 64.93 | 1.95 |
| 52 Week Low | $31.40 | $47.25 |
| 52 Week High | $96.43 | $111.29 |
Technical Indicators
Market Signals| Indicator | UPST | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 71.16 |
| Support Level | $42.27 | $57.44 |
| Resistance Level | $45.65 | $59.30 |
| Average True Range (ATR) | 2.51 | 2.14 |
| MACD | 1.47 | 0.82 |
| Stochastic Oscillator | 92.83 | 91.35 |
Price Performance
Historical ComparisonAbout UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.